TGTX - TG Therapeutics Inc Stock Price, Fair Value and News

$31.61+0.98 (+3.20%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TGTX Price Action

Last 7 days

-5.4%

Last 30 days

-6.2%

Last 90 days

-0.9%

Trailing 12 Months

-5.3%

TGTX RSI Chart

TGTX Valuation

Market Cap

5.0B

Price/Earnings (Trailing)

11.21

Price/Sales (Trailing)

9.43

EV/EBITDA

46.09

Price/Free Cashflow

-71.45

TGTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TGTX Fundamentals

TGTX Revenue

Revenue (TTM)

531.9M

Rev. Growth (Yr)

92.79%

Rev. Growth (Qtr)

14.57%

TGTX Earnings

Earnings (TTM)

447.5M

Earnings Growth (Yr)

10.0K%

Earnings Growth (Qtr)

1.3K%

TGTX Profitability

EBT Margin

16.50%

Return on Equity

73.69%

Return on Assets

43.65%

Free Cashflow Yield

-1.4%

TGTX Investor Care

Shares Dilution (1Y)

1.99%

Diluted EPS (TTM)

2.79

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	386.4M	454.1M	531.9M	0
2024	289.3M	346.7M	264.8M	329.0M
2023	8.6M	24.1M	189.8M	233.7M
2022	7.9M	7.0M	5.0M	2.8M
2021	907.0K	2.4M	4.4M	6.7M
2020	152.0K	152.0K	152.0K	152.0K
2019	337.0K	152.0K	152.0K	152.0K
2018	224.8K	297.5K	370.3K	443.0K
2017	283.1K	240.5K	231.5K	152.0K
2016	229.4K	290.5K	322.5K	323.0K
2015	86.9K	118.8K	150.7K	182.6K
2014	36.9K	42.9K	49.0K	55.0K
2013	53.5K	87.5K	120.6K	30.8K
2012	0	0	0	92.1K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

CEO	Mr. Michael S. Weiss Esq.
WEBSITE	tgtherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	244

TG Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for TG Therapeutics Inc? What does TGTX stand for in stocks?

TGTX is the stock ticker symbol of TG Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TG Therapeutics Inc (TGTX)?

As of Wed Dec 03 2025, market cap of TG Therapeutics Inc is 5.02 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TGTX stock?

You can check TGTX's fair value in chart for subscribers.

Is TG Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TGTX is over valued or under valued. Whether TG Therapeutics Inc is cheap or expensive depends on the assumptions which impact TG Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TGTX.

What is TG Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, TGTX's PE ratio (Price to Earnings) is 11.21 and Price to Sales (PS) ratio is 9.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TGTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on TG Therapeutics Inc's stock?

In the past 10 years, TG Therapeutics Inc has provided 0.084 (multiply by 100 for percentage) rate of return.